Literature DB >> 25690500

Benzathine Penicillin G for the Management of RHD: Concerns About Quality and Access, and Opportunities for Intervention and Improvement.

Rosemary Wyber1, Kathryn Taubert2, Stephen Marko3, Edward L Kaplan4.   

Abstract

Benzathine penicillin G is an important antibiotic for the treatment and prevention of group A streptococcal infections associated with rheumatic fever and rheumatic heart disease. However, as rheumatic heart disease has receded as a public health priority in most high-income settings, attention to the supply, manufacture, and accessibility of benzathine penicillin G has declined. Concerns about the quality, efficacy, and innovation of the drug have emerged following plasma analysis and anecdotal reports from low-resource settings. This review collates core issues in supply and delivery of benzathine penicillin G as a foundation for concerted efforts to improve global quality and access. Opportunities for intervention and improvement are explored.
Copyright © 2013 World Heart Federation (Geneva). Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2013        PMID: 25690500     DOI: 10.1016/j.gheart.2013.08.011

Source DB:  PubMed          Journal:  Glob Heart


  19 in total

1.  Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD).

Authors:  Oliver D Montagnat; Graham R Webster; Jürgen B Bulitta; Cornelia Landersdorfer; Rosemary Wyber; Meru Sheel; Jonathan R Carapetis; Ben J Boyd
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

2.  Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling.

Authors:  Jessica R Tait; Timothy C Barnett; Kate E Rogers; Wee Leng Lee; Madhu Page-Sharp; Laurens Manning; Ben J Boyd; Jonathan R Carapetis; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2022-06-29       Impact factor: 5.758

3.  Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.

Authors:  Rosemary Wyber; Ben J Boyd; Samantha Colquhoun; Bart J Currie; Mark Engel; Joseph Kado; Ganesan Karthikeyan; Mark Sullivan; Anita Saxena; Meru Sheel; Andrew Steer; Joseph Mucumbitsi; Liesl Zühlke; Jonathan Carapetis
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

4.  Health policy: Reducing rheumatic heart disease in Africa -- time for action.

Authors:  Andrea Beaton; Craig Sable
Journal:  Nat Rev Cardiol       Date:  2016-03-03       Impact factor: 32.419

Review 5.  Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.

Authors:  Angela E Rankine-Mullings; Shirley Owusu-Ofori
Journal:  Cochrane Database Syst Rev       Date:  2017-10-10

6.  Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis.

Authors:  Shannon Marantelli; Robert Hand; Jonathan Carapetis; Andrea Beaton; Rosemary Wyber
Journal:  Heart Asia       Date:  2019-06-20

7.  Out-of-pocket costs in rheumatic heart disease care: A major barrier to equity in cardiovascular health.

Authors:  Ana Olga Mocumbi
Journal:  Indian Heart J       Date:  2021-02-02

Review 8.  New developments in anti-malarial target candidate and product profiles.

Authors:  Jeremy N Burrows; Stephan Duparc; Winston E Gutteridge; Rob Hooft van Huijsduijnen; Wiweka Kaszubska; Fiona Macintyre; Sébastien Mazzuri; Jörg J Möhrle; Timothy N C Wells
Journal:  Malar J       Date:  2017-01-13       Impact factor: 2.979

9.  Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews.

Authors:  Stephen Nurse-Findlay; Melanie M Taylor; Margaret Savage; Maeve B Mello; Sanni Saliyou; Manuel Lavayen; Frederic Seghers; Michael L Campbell; Françoise Birgirimana; Leopold Ouedraogo; Morkor Newman Owiredu; Nancy Kidula; Lee Pyne-Mercier
Journal:  PLoS Med       Date:  2017-12-27       Impact factor: 11.069

10.  Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.

Authors:  Angela E Rankine-Mullings; Shirley Owusu-Ofori
Journal:  Cochrane Database Syst Rev       Date:  2021-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.